Clinical trials: Osteopenia or Osteoporosis
Osteopenia, Osteoporosis, Sarcopenia
Functional and Metabolic Effects of Fonte Fausta® Water on Bone and Muscle Health in Osteoporotic Patients
This clinical study investigates the effects of Fonte Fausta® water on bone and muscle metabolism, as well as quality of life, in patients with osteoporosis or osteopenia, with or without sarcopenia.
- Trial name
- FOCUS (NCT06851676)
- Testing
- water supplemented by calcium
- Where
- Italy
- Volunteers
- 100 people
- Sponsor
- ANTIMO
Osteopenia or Osteoprosis
Long-term Effect of Electromagnetic Field in Treatment of Patients With Osteopenia or Osteoporosis
Osteoporosis is the most prevalent metabolic bone disease. Although osteoporosis is widely considered to be much more prevalent in women approximately 39% of new osteoporotic fractures estimated to have occurred worldwide in 2000…
- Trial name
- NCT04608162
- Testing
- Pulsed Electromagnetic Field (PEMF), Exercise Program
- Where
- Saudi Arabia
- Volunteers
- 120 people
- Sponsor
- Umm Al-Qura University
Osteopenia or Osteoporosis
The Effect of Effervescent Alendronate on Bone Turnover
64 postmenopausal women are randomized to treatment with either effervescent and buffered alendronate or conventional alendronate -both 70mg weekly for 16 weeks to see if bone turnover is suppressed to the same extent as in the…
- Trial name
- NCT05325515
- Testing
- Conventional alendronate, Effervescent and buffered alendronate
- Where
- Denmark
- Volunteers
- 64 people
- Sponsor
- Aarhus University Hospital
Osteoporosis Risk, Bone Loss
Comparison of Bone Microarchitecture Analysed by HRpQCT and pQCT in Pathologies With Bone Loss and/or Muscle Loss
The study aims to utilize medical devices, such as the Xtreme CT and XCT 3000, to assess bone and muscle microarchitecture for various pathologies.
- Trial name
- MICROS (NCT06541548)
- Testing
- HR-pQCT, pQCT, DEXA
- Where
- France
- Volunteers
- 1,000 people
- Sponsor
- Centre Hospitalier Universitaire de Saint Etienne
Breast Neoplasms, Osteoporosis
Zoledronic Acid - Letrozole Adjuvant Synergy Trial (ZFAST) - Cancer Treatment Related Bone Loss in Postmenopausal Women With Estrogen Receptor Positive and/or Progesterone Receptor Positive Breast Cancer Receiving Adjuvant Hormonal Therapy
This protocol is designed to compare the effect on bone of Zoledronic Acid 4 mg every 6 months when given upfront versus delayed start (based on a post-baseline BMD T- Score below -2.0 SD at either the lumbar spine or total hip…
- Trial name
- NCT00050011
- Testing
- Zoledronic Acid, Letrozole
- Where
- 44 sites in United States, Puerto Rico
- Volunteers
- 602 people
- Sponsor
- Novartis Pharmaceuticals
Breast Cancer, Osteoporosis
Zoledronate in Treating Osteopenia or Osteoporosis in Postmenopausal Women Receiving Letrozole for Stage I, Stage II, or Stage IIIA Primary Breast Cancer
RATIONALE: Zoledronate may reduce bone loss in patients receiving letrozole for breast cancer. PURPOSE: This clinical trial is studying how well zoledronate works in treating osteopenia or osteoporosis in postmenopausal women…
- Trial name
- NCT00436917
- Testing
- zoledronic acid, Letrozole as adjuvant therapy
- Where
- 2 sites in United States
- Volunteers
- 60 people
- Sponsor
- Mayo Clinic
Postmenopausal Osteoporosis
A Study of Ibandronate (Boniva) to Evaluate Satisfaction in Women With Post-Menopausal Osteoporosis or Osteopenia
This study will investigate participant satisfaction (including compliance, preference, tolerability) with once-monthly Bonviva in women with post-menopausal osteoporosis or osteopenia transitioned from once-weekly alendronate or…
- Trial name
- NCT02604836
- Testing
- Ibandronate
- Where
- 142 sites in United States
- Volunteers
- 1,711 people
- Sponsor
- Hoffmann-La Roche
Osteoporosis
The Effects of Ibandronate or Teriparatide Therapy on Bone Histology and Biochemical Indices in Patients on Hemodialysis With Low Bone Mineral Density
Hemodialysis patients with low bone density (total hip T-score <-2.5) will be assigned to receive teriparatide (those with histologic confirmation of adynamic bone disease) or ibandronate (subjects with increased osteoclast…
- Trial name
- NCT00446589
- Testing
- ibandronate, teriparatide
- Where
- Greece
- Volunteers
- 19 people
- Sponsor
- Papageorgiou General Hospital
Osteoporosis, Osteopenia
Controlled Study of ONO-5334 in Postmenopausal Women With Osteopenia or Osteoporosis
The purpose of this study is to evaluate the efficacy and safety of ONO-5334 in postmenopausal women with osteopenia or osteoporosis.
- Trial name
- NCT00532337
- Testing
- ONO-5334
- Where
- Netherlands
- Volunteers
- 285 people
- Sponsor
- Ono Pharma USA Inc
Osteoporosis, Postmenopausal, Osteopenia
High-Intensity Laser Therapy and Physiotherapy for Bone Health in Postmenopausal Women: A Randomized Trial
The goal of this clinical trial is to learn if adding high-intensity laser therapy (HILT) to a physiotherapy programme helps bone health in women after menopause who have low bone density (osteopenia or osteoporosis).
- Trial name
- NCT07734922
- Testing
- High-Intensity Laser Therapy, Standardised Physiotherapy Programme
- Where
- Romania
- Volunteers
- 40 people
- Sponsor
- Iuliu Hatieganu University of Medicine and Pharmacy
Arthralgia
Changes in Knee Articular Cartilage Volume in Women on Aromatase Inhibitors
Many women with breast cancer are treated with a class of drugs called aromatase inhibitors (mainly letrozole or anastrozole), which lowers the amount of estrogen being produced in the body.
- Trial name
- NCT00111241
- Testing
- aromatase inhibitors (letrozole, anastrozole)
- Where
- Australia
- Volunteers
- 115 people
- Sponsor
- Monash University
Breast Cancer, Osteoporosis
Zoledronate in Preventing Bone Loss in Postmenopausal Women Who Are Receiving Letrozole for Stage I, Stage II, or Stage IIIA Breast Cancer
RATIONALE: Estrogen can cause the growth of breast cancer cells. Hormone therapy using letrozole may fight breast cancer by lowering the amount of estrogen the body makes.
- Trial name
- NCT00107263
- Testing
- letrozole, zoledronic acid
- Volunteers
- 558 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Osteopenia or Osteoporosis
Strenght Training in Osteoporosis Prevention
The study involves 120 women over the age of 50. All participants in the study take part in high-intensity strength training for 10 months. In addition, half of the participants receive vitamin D3 at a dose of 4,000 IU/day.
- Trial name
- SPORT (NCT06733064)
- Testing
- Supplementation of vitamin D3
- Where
- 2 sites in Poland
- Volunteers
- 120 people
- Sponsor
- Mateusz Karnia
Osteopenia
Zoledronic Acid in the Prevention of Bone Loss in Postmenopausal Women With Osteopenia, 45 Years of Age and Older
Osteoporosis prevention is important in patients with osteopenia (low bone density). This study will test the safety and efficacy of zoledronic acid in patients diagnosed with osteopenia.
- Trial name
- NCT00132808
- Testing
- Zoledronic Acid
- Where
- United States
- Volunteers
- 581 people
- Sponsor
- Novartis Pharmaceuticals
Bone Demineralization
Alendronate for Prevention of AntiRetroviral Therapy-associated Bone Loss
Antiretroviral therapy (ART) initiation is associated with a significant loss of bone mineral density (BMD), characterised by increases in bone turnover, which is largely limited to the first 48 weeks of therapy.
- Trial name
- APART (NCT02322099)
- Testing
- Alendronate, calcium carbonate and colecalciferol, Tenofovir disoproxil
- Where
- 2 sites in Ireland
- Volunteers
- 53 people
- Sponsor
- University College Dublin
Osteoporosis, Osteopenia
Hormonal and Bone Turnover Marker Response to an Acute Bout of Resistance or Plyometric Exercise
We are interested in determining if there exist a short-term response in the serum markers and hormones that participate in the regulation of bone tissue formation and breakdown to a single, high-intensity exercise session of…
- Trial name
- NCT00572871
- Testing
- plyometric exercise, resistance exercise, No exercise
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- University of Missouri-Columbia
Osteoporotic Fracture
Effectiveness or Orthopedic Intervention in Osteoporosis Management After a Fracture of the Hip With Cost-Benefit Analysis
Patients who present with fragility fractures are consistently under-evaluated and under-treated for underlying osteoporosis. This point of care represents a lost opportunity to prevent future fractures.
- Trial name
- NCT02239523
- Testing
- Letter Group, Intervention Group
- Where
- Israel
- Volunteers
- 200 people
- Sponsor
- Shaare Zedek Medical Center
Idiopathic Inflammatory Myopathies, Osteoporosis, Osteopenia
Treating Idiopathic Inflammatory Myopathies Related Reduced Bone Mineral Density With Denosumab or Zoledronic Acid
Idiopathic inflammatory myopathies (IIM) patients are at high risk of development of reduced bone mineral density due to impairment of functional status due to the disease and a relatively high dose of glucocorticoid use for the…
- Trial name
- NCT04034199
- Testing
- Denosumab, Zoledronic Acid
- Where
- Hong Kong
- Volunteers
- 40 people
- Sponsor
- Kwong Wah Hospital
Low Bone Mineral Density, Postmenopausal Osteoporosis
Eldecalcitol and Calcitriol in Postmenopausal Women With Low Bone Mineral Density or Mild Osteoporosis
To investigate the efficacy and safety of eldecalcitol in postmenopausal women with low bone mineral density (BMD) or mild osteoporosis through a randomized, open-label, parallel controlled trial with calcitriol as the control.
- Trial name
- EFFECT (NCT05902078)
- Testing
- Eldecalcitol capsules, Calcitriol capsules
- Where
- 21 sites in China
- Volunteers
- 300 people
- Sponsor
- Shanghai Jiao Tong University Affiliated Sixth People's Hospital
Critical Illness, Osteoporosis
Bone Loss Prevention With Zoledronic Acid or Denosumab in Critically Ill Adults
The Bone Zone trial is a prospective, multi-centre, double-blind, phase II, randomised controlled trial evaluating the effect of denosumab or zoledronic acid compared to placebo on change in bone mineral density over one year in…
- Trial name
- BoneZone (NCT04608630)
- Testing
- Denosumab 60 MG/ML, Zoledronic Acid 5Mg/Bag 100Ml Inj, Sodium Chloride 0.9% or 5% Dextrose Intravenous
- Where
- 22 sites in Australia, New Zealand
- Volunteers
- 450 people
- Sponsor
- Australian and New Zealand Intensive Care Research Centre